CalcMyPeptide
Clinical / PharmaceuticalAlso known as: DDAVP, Minirin, 1-desamino-8-D-arginine vasopressin

Desmopressin

Desmopressin (DDAVP) is a highly engineered, synthetic evolution of the endogenous human antidiuretic hormone (Vasopressin). Through precise amino acid substitution, its antidiuretic potency is massively magnified while its dangerous vasoconstrictive properties are entirely eliminated. Clinically, it is the absolute gold standard to aggressively halt catastrophic fluid loss in central diabetes insipidus, treat severe surgical bleeding disorders (Hemophilia A), and manage nocturnal enuresis.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: High1 peer-reviewed citation

Quick Stats

Half-Life~1.5-2.5 hours
Dose Range10-40 mcg/day (intranasal) or 0.1-0.4 mg oral
Frequency1-3× daily
Vial SizesN/A (oral)
BioavailabilityIntranasal, oral tablets, sublingual, or injection
Year Developed1972

Scientific Data

Molecular Formula
C46H64N14O12S2
Molecular Weight
1069.2 g/mol
CAS Number
PubChem ID

Mechanism of Action

Desmopressin (DDAVP) is a synthetic analog of the endogenous antidiuretic hormone arginine vasopressin (AVP). By modifying AVP — deaminating the N-terminus and substituting D-arginine for L-arginine — developers increased its antidiuretic potency while almost completely eliminating the vasopressor (blood pressure-raising) effect.

It acts selectively on V2 receptors in the renal collecting ducts, increasing water reabsorption and concentrating urine. It is widely used to treat diabetes insipidus, severe bedwetting, and mild hemophilia A (by releasing von Willebrand factor).

Source: PMID: 3527577

Background & History

Desmopressin (DDAVP) is among the most widely prescribed peptide drugs globally. Developed in 1967 by modifying natural vasopressin, it solved the problem of vasopressin's short half-life and blood pressure effects. Used daily by millions of patients with diabetes insipidus and nocturnal enuresis. Also used pre-operatively in mild hemophilia A to boost factor VIII levels without transfusion.

Research Use Cases

  • Central diabetes insipidus
  • Nocturnal enuresis
  • Hemophilia A
  • Von Willebrand disease Type 1

Dosing Protocol

Typical Dose10-40 mcg/day (intranasal) or 0.1-0.4 mg oral
Frequency1-3× daily
Half-Life3 hours

Dosing Protocols

Standard Dose (Oral)

Dose
100 - 200 mcg
Frequency
1-3x daily
Note: FDA-approved for diabetes insipidus. Often taken at bedtime for nocturia/enuresis.

Body-Weight Dosing Reference

Estimated doses extrapolated from the published research range of 1040 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.

WeightLowTargetHigh
120 lb(54 kg)8 mcg19 mcg31 mcg
140 lb(63 kg)9 mcg22 mcg36 mcg
160 lb(73 kg)10 mcg26 mcg42 mcg
180 lb(82 kg)12 mcg29 mcg47 mcg
200 lb(91 kg)13 mcg32 mcg52 mcg
220 lb(100 kg)14 mcg36 mcg57 mcg
250 lb(113 kg)16 mcg40 mcg65 mcg

💉 For exact syringe units based on your vial concentration, use the Desmopressin Reconstitution Calculator →

Administration

Route
Oral tablets, sublingual melt, or intranasal spray
Timing
Usually at bedtime for enuresis.
Fasting Required?
No — food timing not critical

Expected Timeline

Acute (1-2 hours)
Significant decrease in urine output and increase in urine osmolality.

Who Is It For?

Diabetes Insipidus / Nocturia

High

Gold-standard therapeutic for central diabetes insipidus and primary nocturnal enuresis.

Safety & Considerations

FDA-approved. Major risk is hyponatremia (water intoxication) due to fluid retention. Fluid intake must be restricted when taking DDAVP. Not for use in individuals with heart failure or uncontrolled hypertension.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Interactions & Contraindications

Avoid concurrent NSAIDs (increase ADH effect/hyponatremia risk). Carbamazepine, chlorpropamide, and SSRIs may potentiate antidiuretic effect. Restrict fluid intake during use.

Synergies & Common Stacks

Desmopressin is the synthetic, clinically superior analogue of vasopressin — they are never combined but represent the same receptor pathway.

Dosing Quick Reference

Desmopressin— Dosing Guide
Dose Range
10-40 mcg/day (intranasal) or 0.1-0.4 mg oral
Half-Life
3 hours
Frequency
1-3× daily
Route
Oral
Clinical / Pharmaceuticalcalcmypeptide.com

Frequently Asked Questions

How is desmopressin different from vasopressin?
Vasopressin raises blood pressure (V1 receptors) and retains water (V2 receptors). Desmopressin is modified to specifically target V2 receptors, retaining water without dangerously elevating blood pressure.

References

  1. Richardson DW, Robinson AG "Desmopressin: a review of its use in diabetes insipidus".” Annals of Internal Medicine (1985). PMID: 3896088

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code